EX-4.2



 Exhibit 4.2 

Execution Copy 
  

 
 WAVE LIFE SCIENCES PTE. LTD. 

INVESTORS’ RIGHTS AGREEMENT 
  







 TABLE OF CONTENTS 

 

									
	 	 	 	 	 	  	Page	 
	1.	 	Definitions	  	 	1	  
			
	2.	 	Registration Rights	  	 	4	  
				
		 	2.1	 	Demand Registration	  	 	4	  
		 	2.2	 	Company Registration	  	 	6	  
		 	2.3	 	Underwriting Requirements	  	 	6	  
		 	2.4	 	Obligations of the Company	  	 	7	  
		 	2.5	 	Furnish Information	  	 	9	  
		 	2.6	 	Expenses of Registration	  	 	9	  
		 	2.7	 	Delay of Registration	  	 	9	  
		 	2.8	 	Indemnification	  	 	9	  
		 	2.9	 	Reports Under Exchange Act	  	 	11	  
		 	2.10	 	Limitations on Subsequent Registration Rights	  	 	12	  
		 	2.11	 	“Market Stand off” Agreement	  	 	12	  
		 	2.12	 	Restrictions on Transfer	  	 	13	  
		 	2.13	 	Termination of Registration Rights	  	 	14	  
			
	3.	 	Information and Observer Rights	  	 	15	  
				
		 	3.1	 	Delivery of Financial Statements	  	 	15	  
		 	3.2	 	Inspection	  	 	16	  
		 	3.3	 	Termination of Information Rights	  	 	16	  
		 	3.4	 	Confidentiality	  	 	16	  
			
	4.	 	Rights to Future Share Issuances	  	 	17	  
				
		 	4.1	 	Right of First Offer	  	 	17	  
		 	4.2	 	Termination	  	 	18	  
			
	5.	 	Additional Covenants	  	 	18	  
				
		 	5.1	 	Insurance	  	 	18	  
		 	5.2	 	Board Matters	  	 	18	  
		 	5.3	 	Successor Indemnification	  	 	19	  
		 	5.4	 	U.S. Tax Matters	  	 	19	  
		 	5.5	 	FCPA	  	 	20	  
		 	5.6	 	Termination of Covenants	  	 	21	  
			
	6.	 	Miscellaneous	  	 	21	  
				
		 	6.1	 	Successors and Assigns	  	 	21	  
		 	6.2	 	Governing Law	  	 	21	  
		 	6.3	 	Counterparts	  	 	22	  
		 	6.4	 	Titles and Subtitles	  	 	22	  
		 	6.5	 	Notices	  	 	22	  
		 	6.6	 	Amendments and Waivers	  	 	22	  
		 	6.7	 	Severability	  	 	23	  


  
 i 









									
		 	6.8	 	Aggregation of Shares	  	 	23	  
		 	6.9	 	Additional Investors	  	 	23	  
		 	6.10	 	Entire Agreement	  	 	23	  
		 	6.11	 	Dispute Resolution	  	 	24	  
		 	6.12	 	Delays or Omissions	  	 	24	  

  

							
	 Schedule A
	  	 	    -	  	  	    Schedule of Investors


  
 ii 








 WAVE LIFE SCIENCES PTE. LTD. 

INVESTORS’ RIGHTS AGREEMENT 

THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the
14th day of August, 2015, by and among Wave Life Sciences Pte. Ltd., a company incorporated in Singapore (the “Company”), each of the investors listed on Schedule A
hereto, each of which is referred to in this Agreement as an “Investor”. 
 RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Ordinary Shares and
possess registration rights, information rights, rights of first offer, and other rights pursuant to an Amended and Restated Shareholders Agreement dated as of January 16, 2015 between the Company and such Investors (the “Shareholders
Agreement”); and 
 WHEREAS, the Existing Investors are holders of at least seventy-five percent (75%) of the
Company’s Ordinary Shares and desire to terminate the Shareholders Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Shareholders Agreement; and 

WHEREAS, certain of the Investors are parties to that certain Series B Preferred Share Subscription Agreement of even date herewith
between the Company and certain of the Investors (the “Subscription Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement by
such Investors and Existing Investors holding at least seventy-five percent (75%) of the Company’s Ordinary Shares and the Company; 

NOW, THEREFORE, the Existing Investors hereby agree that the Shareholders Agreement shall be superseded and replaced in its entirety by
this Agreement, and the parties to this Agreement further agree as follows: 
  

	 	1.	Definitions. For purposes of this Agreement: 

 1.1 “Affiliate” means,
with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of
such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person. 

1.2 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under
the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a
material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a
material fact required to be stated therein, or 







 
necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the
Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.3 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Ordinary Shares, including options and warrants. 
 1.4 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.5 “Excluded Registration”
means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a share option, share purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Ordinary
Shares being registered is Ordinary Shares issuable upon conversion of debt securities that are also being registered. 
 1.6
“Fidelity” means Fidelity Management & Research Company and its Affiliates. 
 1.7 “FOIA Party”
means a Person that, in the reasonable determination of the Board of Directors, may be subject to, and thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552
(“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement. 

1.8 “Foresite” means Foresite Capital Fund III, L.P. 

1.9 “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form
under the Securities Act subsequently adopted by the SEC. 
 1.10 “Form S-3” means such form under the Securities Act as in
effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.11 “GAAP” means generally accepted accounting principles in the United States. 

1.12 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.13 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

  
 2 








 1.14 “Initiating Holders” means, collectively, Holders who properly initiate a
registration request under this Agreement. 
 1.15 “Investor Ordinary Shares” means the Ordinary Shares held by the
Investors on the date hereof. 
 1.16 “IPO” means the Company’s first underwritten public offering of its Ordinary
Shares under the Securities Act. 
 1.17 “Jennison” means “(i) Jennison Global Healthcare Master Fund, Ltd. and
(ii) without duplication of the immediately preceding clause (i), each Investor that is an advisory client of Jennison Associates LLC and each successor or affiliated investment advisor to each such Investor. 

1.18 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least
300,000 shares of Registrable Securities (as adjusted for any share split, share dividend, combination, or other recapitalization or reclassification effected after the date hereof), and each of Jennison and New Leaf for so long as such Investors
holds the number of shares of Registrable Securities it holds on the date hereof (as adjusted for any share split, share dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.19 “New Leaf” means New Leaf Growth Fund I, L.P. 

1.20 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.21 “Ordinary Shares” means the ordinary shares in the Company’s share capital. 

1.22 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.23 “Registrable Securities” means (i) the Ordinary Shares issuable or issued upon conversion of the Series B
Preferred Shares and (ii) the Investor Ordinary Shares; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to
Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.24 “Registrable Securities then outstanding” means the number of shares determined by adding the number of Ordinary Shares
in issue that are Registrable Securities and the number of Ordinary Shares issuable upon conversion of the Series B Preferred Shares in issue. 

  
 3 








 1.25 “Restated Articles” means the Company’s Memorandum of Association and
Articles of Association that took effect on or about the date of the Subscription Agreement. 
 1.26 “Restricted
Securities” means the securities of the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof. 

1.27 “SEC” means the Securities and Exchange Commission. 

1.28 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.29 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.30 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.31 “Selling Expenses” means all underwriting discounts, selling commissions, and share transfer Taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

1.32 “Series B Preferred Shares” means the Company’s Series B Preferred Shares. 

Capitalized terms not otherwise defined in this Agreement shall have the meanings ascribed to them in the Subscription Agreement. 

 

	 	2.	Registration Rights. The Company covenants and agrees as follows: 

 2.1 Demand
Registration. 
 (a) Form S-1 Demand. If at any time after one hundred eighty (180) days after the effective date of the
registration statement for the IPO, the Company receives a request from Holders of fifty percent (50%) of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to fifty percent
(50%) of the Registrable Securities then outstanding having an anticipated aggregate offering price, net of Selling Expenses, of at least $25 million), then the Company shall (x) within ten (10) days after the date such request is
given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the
Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such
registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and
2.3. 

  
 4 








 (b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration
statement, the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to Registrable Securities of such
Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than
the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering
all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case,
subject to the limitations of Subsections 2.1(c) and 2.3. 
 (c) Notwithstanding the foregoing obligations, if the Company
furnishes to Holders requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be
materially detrimental to the Company and its shareholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action
would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide
business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing,
and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided,
however, that the Company may not invoke this right more than once in any twelve (12) month period. 
 (d) The Company shall
not be obligated to effect, or to take any action to effect, any registration (i) after the Company has effected one registration pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of
Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Subsection 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a
Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected one registration
pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time
as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand
registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 

  
 5 








 2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for shareholders other than the Holders) any of its Ordinary Shares under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the
provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such
withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and
shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the managing
underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would
be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the
Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the
underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 
 (b) In connection with
any offering involving an underwriting of the Company’s share capital pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept
the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total
number of securities, including Registrable Securities, requested by shareholders to be included in such offering 

  
 6 








 
exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the
Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If
the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders
in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in
accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of
Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the
offering be reduced below twenty percent (20-%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination
described above and no other shareholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability
company, or corporation, the partners, members, retired partners, retired members, shareholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any
trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable
Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 
 2.4 Obligations of the
Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
eighty (180) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred eighty (180) day period shall be extended for a period
of time equal to the period the Holder refrains, at the request of an underwriter of Ordinary Shares (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of
Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred eighty (180) day period shall be extended for up to eighteen (18) days,
if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 
 (b) prepare and file with the
SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities
covered by such registration statement; 

  
 7 








 (c) furnish to the selling Holders such numbers of copies of a prospectus, including a
preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any
such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available
for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 

  
 8 








 2.5 Furnish Information. It shall be a condition precedent to the obligations of the
Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by
it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to
exceed $25,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any
registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall
bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration
pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects
of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not
forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata
on the basis of the number of Registrable Securities registered on their behalf. 
 2.7 Delay of Registration. No Holder shall have
any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
Section 2. 
 2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the
partners, members, officers, directors, and shareholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such
Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses
reasonably incurred thereby in connection with investigating or defending any claim or proceeding from 

  
 9 








 
which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid
in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of
or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection
with such registration. 
 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold
harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company,
any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that
such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such
selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses
are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent
of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and
2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including
any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying
party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been
given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one
counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due
to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such
action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure
to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

  
 10 








 (d) To provide for just and equitable contribution to joint liability under the Securities Act
in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a
court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for
indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will
contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the
indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no
Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided
further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering
received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this
Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S 3, the Company shall: 

  
 11 








 (a) make and keep available adequate current public information, as those terms are understood
and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 
 (b)
use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting
requirements); and 
 (c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to
the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the
IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S 3 (at any time after the Company
so qualifies); and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has
become subject to the reporting requirements under the Exchange Act) or pursuant to Form S 3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder
(i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will
not reduce the number of the Registrable Securities of the Holders that are included; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9.

 2.11 “Market Stand off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the
managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of its Ordinary Shares or any other equity securities under the Securities Act on a registration statement on Form S-1
or Form S-3, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the IPO, or such other period as may be requested by the Company or an underwriter
to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or
NYSE Rule 472(f)(4), or any successor 

  
 12 








 
provisions or amendments thereto), or ninety (90) days in the case of any registration other than the IPO, or such other period as may be requested by the Company or an underwriter to
accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE
Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to
purchase; or otherwise transfer or dispose of, directly or indirectly, any Ordinary Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Ordinary Shares held immediately before the effective date of
the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction
described in clause (i) or (ii) above is to be settled by delivery of Ordinary Shares or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall only apply to the IPO and shall not apply to
the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of
the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and
directors are subject to the same restrictions. The underwriters in connection with such registration are intended third party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions
hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are
necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the
number of shares subject to such agreements. 
 2.12 Restrictions on Transfer. 

(a) The Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue
stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities
Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this
Agreement. 
 (b) Each certificate, instrument, or book entry representing (i) the Registrable Securities, and (ii) any other
securities issued in respect of the securities referenced in clauses (i) and (ii), upon any share split, share dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of
Subsection 2.12(c)) be notated with a legend substantially in the following form: 
 THE SECURITIES REPRESENTED HEREBY HAVE BEEN
ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY
REQUIREMENTS OF SAID ACT. 

  
 13 








 THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN
AGREEMENT BETWEEN THE COMPANY AND THE SHAREHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to
the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of
this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give
notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested
by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect
that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or
transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the
terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such
Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book
entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such
certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities
Act. 
 2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable
Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 
 (a) the
closing of a Deemed Liquidation Event, as such term is defined in the Restated Articles; 
 (b) such time after the restrictions
contemplated by Subsection 2.11 have lapsed when as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without
registration; and 

  
 14 








 (c) the third anniversary of the IPO. 

 

	 	3.	Information and Observer Rights. 

 3.1 Delivery of Financial Statements. The
Company shall deliver to each Major Investor, provided that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company, provided further that neither Foresite, Fidelity Jennison nor New Leaf
may be determined to be a competitor of the Company in any event for any purposes hereunder: 
 (a) as soon as practicable, but in any
event within one hundred twenty (120) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of
shareholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b) as soon as practicable, but in any event within forty five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements
may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the
next fiscal year (collectively, the “Budget”), prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets
prepared by the Company; 
 (d) of the Company and its results of operation for the periods specified therein; and 

(e) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major
Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide information the disclosure of which would adversely affect the attorney-client
privilege between the Company and its counsel. 
 In addition, for so long as each of Foresite and Fidelity, respectively, remains a Major
Investor and is bound by confidentiality obligations to the Company, the Company shall deliver to such Major Investor copies of all presentations, meeting agendas, notices, minutes, consents and other materials that it provides to the Company’s
Board of Directors within two (2) business days of and in the same manner that such materials are provided to the Board of Directors, unless the Company reasonably determines that such disclosure would adversely affect the attorney-client
privilege between the Company and its counsel. Notwithstanding the foregoing, the 

  
 15 








 
Company shall not be obligated to provide the information referenced in the immediately preceding sentence to Foresite at any time that Foresite has the right to exclusively designate the Series
B Designee (as such term is defined in the Voting Agreement) to the Company’s Board of Directors. 
 If, for any period, the Company
has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of
the Company and all such consolidated subsidiaries. 
 Notwithstanding anything else in this Subsection 3.1 to the contrary, the
Company may cease providing the information set forth in this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it
reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as
the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 

3.2 Inspection. The Company shall permit each Major Investor (provided that the Board of Directors has not reasonably determined
that such Major Investor is a competitor of the Company, and provided further that neither Foresite, Fidelity, Jennison nor New Leaf may be determined to be a competitor of the Company in any event for any purposes hereunder), at such Major
Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as
may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information the disclosure of which would adversely affect
the attorney-client privilege between the Company and its counsel. 
 3.3 Termination of Information Rights. The covenants set forth
in Subsection 3.1 and Subsection 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements
of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Articles, whichever event occurs first. 

3.4 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless
such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has been independently developed or conceived by the
Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company;
provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their


  
 16 








 
services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees
to be bound by the provisions of this Subsection 3.5; (iii) to any existing Affiliate, partner, member, shareholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor
informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such
disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 
  

	 	4.	Rights to Future Share Issuances. 

 4.1 Right of First Offer. Subject to the terms
and conditions of this Subsection 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to
apportion the right of first offer hereby granted to it. in such proportions as it deems appropriate, among (i) itself and (ii) its Affiliates; provided that each such Affiliate (x) is not a competitor (provided that neither
Foresite, Fidelity nor Jennison may be determined to be a competitor of the Company in any event for any purpose hereunder) or FOIA Party, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors and
(y) agrees to enter into this Agreement and the Voting Agreement (as defined in the Subscription Agreement), as an “Investor” under each such agreement (provided that any competitor or FOIA Party shall not be entitled to
any rights as a Major Investor under Subsections 3.1, 3.2 and 4.1 hereof, and provided further that neither Foresite nor any of its Affiliates, Fidelity nor Jennison may be determined to be a competitor of the Company in any
event for any purposes hereunder). 
 (a) The Company shall give notice (the “Offer Notice”) to each Major Investor,
stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Ordinary Shares then held by such Major Investor (including all Ordinary Shares then
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Series B Preferred Shares and any other Derivative Securities then held by such Major Investor) bears to the total Ordinary Shares of the Company then
outstanding (assuming full conversion and/or exercise, as applicable, of all Series B Preferred Shares and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor
that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has
given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were
entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Ordinary Shares issued and held, 

  
 17 








 
or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of all Series B Preferred Shares and any other Derivative Securities then held, by such Fully Exercising
Investor bears to the Ordinary Shares issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Series B Preferred Shares and any other Derivative Securities then held, by all Fully Exercising
Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of one hundred and twenty (120) days of the date that the Offer Notice is given and the date
of initial sale of New Securities pursuant to Subsection 4.1(c). 
 (c) If all New Securities referred to in the Offer Notice are
not elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining
unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of
the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless
first reoffered to the Major Investors in accordance with this Subsection 4.1. 
 (d) The right of first offer in this Subsection 4.1
shall not be applicable to (i) Exempted Securities (as defined in the Company’s Certificate of Incorporation); and (ii) Ordinary Shares issued in the IPO. 

4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or effect
(i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as
such term is defined in the Restated Articles, whichever event occurs first and, as to each Major Investor, in accordance with Subsection 4.1(e). 
  

	 	5.	Additional Covenants. 

 5.1 Insurance. The Company shall use its commercially
reasonable efforts to obtain, within ninety (90) days of the date hereof, from financially sound and reputable insurers Directors and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board of Directors,
and will use commercially reasonable efforts to cause such insurance to be maintained until such time as the Board of Directors determines that such insurance should be discontinued. Such insurance shall not be cancelable by the Company without
prior approval by the Board of Directors. 
 5.2 Board Matters. Unless otherwise determined by the vote of a majority of the
directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the non-employee directors for all reasonable out-of-pocket travel expenses incurred (consistent
with the Company’s travel policy) in connection with attending meetings of the Board of Directors. 

  
 18 








 5.3 Successor Indemnification. If the Company or any of its successors or assignees
consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the
Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Restated Articles, or elsewhere, as
the case may be. 
 5.4 U.S. Tax Matters. 

Immediately after the Completion, to the Company’s knowledge (after consultation with its tax advisors), neither the Company nor any
subsidiary of the Company shall be a “Controlled Foreign Corporation” (a “CFC”) as defined in the U.S. Internal Revenue Code of 1986, as amended (or any successor thereto) (the “Code”). The Company shall
make due inquiry with its tax advisors on at least an annual basis regarding the Company’s status as a CFC and, if it is determined that the Company is or may be a CFC, regarding whether any portion of the Company’s income is “Subpart
F Income” (as defined in Section 952 of the Code). No later than sixty (60) days following the end of each taxable year of the Company, the Company shall provide to the Investors the Company’s capitalization table as of the end
of the last day of such taxable year. In addition, the Company shall provide the Investors with reasonable access to such other Company information as may be necessary for the Investors to determine the Company’s status as a CFC and to
determine whether any Investor is required to report its pro rata portion of the Company’s “Subpart F Income” on its United States federal income tax return, or to allow the Investors to otherwise comply with applicable United States
federal income tax laws. In the event that the Company is determined by its Company’s tax advisors, or by counsel or accountants for any Investor, to be a CFC, the Company agrees to use commercially reasonable efforts (consistent with the
Company’s overall business objectives and strategies) to (i) avoid generating Subpart F Income; and (ii) annually make dividend distributions to each Investor, to the extent permitted by law and subject to available cash, in a per
share amount calculated by reference to fifty percent (50%) of any income of the Company that would have been deemed distributed per share to the Investors pursuant to Section 951(a) of the Code. 

After consultation with its tax advisors, the Company does not believe that it or any of its subsidiaries is currently a “passive foreign
investment company” within the meaning of Section 1297 of the Code (“PFIC”). The Company shall use commercially reasonable efforts to avoid being a PFIC within the meaning of Section 1297 of the Code, taking into
account the Company’s overall business objectives and strategies. In connection with any “Qualified Electing Fund” election made by any Investor (or its beneficial owners) pursuant to Section 1295 of the Code or any
“Protective Statement” filed by any Investor (or its beneficial owners) pursuant to U.S. Treasury Regulation Section 1.1295-3, as amended (or any successor thereto), the Company shall provide an annual information statement to such
Investor, as required by the applicable Treasury Regulations in form and substance as soon as reasonably practicable following the end of each taxable year of such Investor (but in no event later than ninety (90) days following the end of each
such taxable year), and shall provide such Investor with access to such other Company information as may be required for purposes of filing United States federal income tax returns of the Investors (or their beneficial owners) in connection with
such “Qualified Electing Fund” election or “Protective Statement”. In the event that any Investor (or 

  
 19 








 
any of its beneficial owners) has made a “Qualified Electing Fund” election and must include in its gross income for a particular taxable year its pro rata share of the Company’s
(or any Company subsidiary’s) earnings and profits pursuant to Section 1293 of the Code, as amended (or any successor thereto), the Company agrees to make a dividend distribution to such Investor (no later than ninety (90) days
following the end of such Investor’s taxable year or, if later, sixty (60) days after the Company is informed by such Investor that it (or any of its beneficial owners) has been required to recognize such an income inclusion) in an amount
equal to fifty percent (50%) of the amount that would be included by such Investor (or its beneficial owners) if such person were a “United States person” as such term is defined in Section 7701(a)(30) of the Code and had such
person made a valid and timely “Qualified Electing Fund” election which was applicable to such taxable year. 
 The Company shall
take such actions, including making an election to be treated as a corporation or refraining from making an election to be treated as a partnership, as may be required to ensure that at all times the Company is treated as a corporation for United
States federal income tax purposes. 
 The Company shall make due inquiry with its tax advisors (and shall cooperate with the
Investors’ tax advisors with respect to such inquiry) on at least an annual basis regarding whether any Investor’s (or any of its beneficial owners’) direct or indirect interest in the Company is subject to the reporting requirements
of either or both of Sections 6038 and 6038B of the Code (and the Company shall duly inform the Investors of the results of such determination), and in the event that any Investor’s (or any of its beneficial owners’) direct or indirect
interest in Company is determined by the Company’s tax advisors or such Investor’s tax advisors to be subject to the reporting requirements of either or both of Sections 6038 and 6038B of the Code, the Company agrees, upon a request from
such Investor, to provide such information to such Investor as may be necessary to fulfil such Investor’s (or its beneficial owners’) obligations thereunder. 

The Company further covenants and agrees that to the extent it has any U.S. tax reporting compliance obligations, it shall engage, within
ninety (90) days following the date upon which the facts and circumstances triggering such tax compliance reporting obligations arise, with a reputable U.S. tax advisory firm to assist the Company with such U.S. tax reporting and compliance
obligations. 
 5.5 FCPA. The Company represents that it shall not (and shall not permit any of its subsidiaries or affiliates or any
of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to any third
party, including any Non-U.S. Official (as (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable
anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the Company,
its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or
anti-corruption law. The Company further represents 

  
 20 








 
that it shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing
systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive information and/or certifications concerning its compliance with
applicable anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Subscription Agreement). The Company shall, and shall cause any direct or indirect subsidiary
or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in
all material respects with all applicable laws. 
 5.6 Termination of Covenants. The covenants set forth in this
Section 5, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or
15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Articles, whichever event occurs first. 
  

	 	6.	Miscellaneous. 

 6.1 Successors and Assigns. The rights under this Agreement may
be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual
Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 100,000 shares of Registrable Securities (subject to appropriate adjustment for share splits, share dividends, combinations, and
other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with
respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of
Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or shareholder of a Holder; (2) who is a Holder’s
Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that
all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this
Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of Singapore. 

  
 21 








 6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S.
federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail during the recipient’s normal
business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or
(iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the
respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, or address as
subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy shall also be sent to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111,
Attn: William C. Hicks, Esq. and if notice is given to Investors, a copy shall also be given to Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, Attn: Brian Patterson. 

6.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding; provided that the Company may
in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to
be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, (i) this Agreement may not be amended
or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being
agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain
Investors may nonetheless, by agreement with the Company, purchase securities in such transaction); provided, however, that if Investors waiving the provisions of Section 4 with respect to a particular transaction purchase securities in
such transaction, any non-waiving Investors shall have the right to purchase a pro rata portion (relative to the amount of such securities purchased by the waiving Investors) of such securities on the same terms and conditions), (ii) no waiver
or amendment of Subsections 2.11 and 3.1 or this clause (ii) that is 

  
 22 








 
adverse to Fidelity shall be effective as to Fidelity without the prior written consent of Fidelity, so long as Fidelity is a Major Investor, (iii) no waiver or amendment of Subsections
2.11 and 3.1 or this clause (iii) that is adverse to Foresite shall be effective as to Foresite without the prior written consent of Foresite, so long as Foresite is a Major Investor, (iv) no waiver or amendment of
Subsections 2.11 and 3.1 or this clause (iv) that is adverse to Jennison shall be effective as to Jennison without the prior written consent of Jennison, so long as Jennison is a Major Investor, (v) no waiver or
amendment of Subsection 3.1 or this clause (v) that is adverse to New Leaf shall be effective as to New Leaf, so long as New Leaf is a Major Investor and (vi) the definition of “Major Investor” may not be changed
without the consent of (a) Fidelity for so long as Fidelity is a Major Investor and (b) Jennison for so long as Jennison is a Major Investor. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder
to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether
any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition,
or provision. 
 6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that
it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Shares. All shares of
Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any
manner they deem appropriate. 
 6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company
issues additional shares of the Company’s Series B Preferred Shares after the date hereof, any purchaser of such Series B Preferred Shares may become a party to this Agreement by executing and delivering an additional counterpart signature page
to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional
Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 
 6.10 Entire Agreement.
This Agreement (including any Schedules hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof
existing between the parties is expressly canceled. Upon the effectiveness of this Agreement and the other Voting Agreement (as defined in the Subscription Agreement), the Shareholders Agreement shall be deemed superseded and replaced in its
entirety by this Agreement, and shall be of no further force or effect. 

  
 23 








 6.11 Dispute Resolution. Any dispute, controversy or claim arising out of or in connection
with this Agreement, including any question regarding its existence, validity, interpretation, performance, breach or termination, shall be referred to and finally resolved by binding arbitration in Singapore in accordance with the Arbitration Rules
of the Singapore International Arbitration Centre (the SIAC Rules) for the time being in force, which rules are deemed to be incorporated by reference. The place of arbitration shall be Singapore. The number of arbitrators shall be one (1), whose
appointment shall be in accordance with the SIAC Rules. The award shall be final and binding on the parties, and judgment upon any award may be entered and enforced in any court having jurisdiction. 

Each Investor irrevocably agrees that, in the event of multiple disputes involving the same or substantially the same facts or issues between
the Company and the Investors, the Company may, in order to facilitate the comprehensive resolution of related disputes, apply to the arbitrator first appointed to hear any such dispute to consolidate the arbitration with any other arbitration or
proposed arbitration involving the Investor and relating to this Agreement. Such arbitrator shall not consolidate such arbitrations unless it determines that (a) there are issues of fact or law common to the arbitrations in questions so that a
consolidated proceeding would be more efficient than separate proceedings, and (b) no party would be prejudiced as a result of such consolidation through undue delay or otherwise. 

6.12 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or
to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law
or otherwise afforded to any party, shall be cumulative and not alternative. 
 [Remainder of Page Intentionally Left Blank] 

  
 24 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 WAVE LIFE SCIENCES PTE. LTD.

		
	By:	 	 /s/ Paul B. Bolno, M.D.

		
	Name:	 	 Paul B. Bolno, M.D.

		
	Title:	 	 President and Chief Executive Officer



 SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	 Foresite Capital Fund III, L.P.

	 By: Foresite Capital Management III, LLC its General Partner

		
	By:	 	 /s/ Dennis D. Ryan

		 	  

		
	Name:	 	 Dennis D. Ryan

		
	Title:	 	 Chief Financial Officer

		
	Dated:	 	 8-11-15

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Fidelity Select Portfolios: Biotechnology Portfolio
		
	By:	 	/s/ Joseph Zambello
		 	  

		
	Name:	 	 Joseph Zambello

		
	Title:	 	 Deputy Treasurer

		
	Dated:	 	  

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund
		
	By:	 	/s/ Joseph Zambello
		 	  

		
	Name:	 	 Joseph Zambello

		
	Title:	 	 Deputy Treasurer

		
	Dated:	 	  

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	RA CAPITAL HEALTHCARE FUND, L.P.
	
	By: RA Capital Management, LLC
	Its: General Partner
		
	By:	 	/s/ Peter Kolchinsky
		 	  

		
	Name:	 	 Peter Kolchinsky

		
	Title:	 	 Authorized Signatory




  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT









 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	BLACKWELL PARTNERS LLC – SERIES A
		
	By:	 	/s/ Eric M. Koehrsen
		 	  

		
	Name:	 	 Eric M. Koehrsen
 Investment Manager

DUMAC, Inc.
 Authorized
Agent

		
	Title:	 	 Authorized Signatory

		
	By:	 	/s/ Jannine M. Lall
		 	  

		
	Name:	 	 Jannine M. Lall
 Assistant Treasurer

DUMAC, Inc.
 Authorized
Agent

		
	Title:	 	 Authorized Signatory




  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT









 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	New Leaf Growth Fund I, L.P.
	
	By: New Leaf Growth Associates I, L.P.
	Its: General Partner
	
	By: New Leaf Venture Management III, L.L.C.
	Its: General Partner
		
	By:	 	/s/ Craig L. Slutzkin
		 	  

		
	Name:	 	 Craig L. Slutzkin

		
	Title:	 	 Chief Financial Officer

		
	Dated:	 	 8-12-15

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Redmile Capital Fund, LP
		
	By:	 	/s/ Jeremy Green
		 	  

		
	Name:	 	 Jeremy Green

		
	Title:	 	 Managing Member of the General Partner and the Investment Manager

		
	Dated:	 	 8/12/2015

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Redmile Capital Offshore Fund, Ltd.
		
	By:	 	/s/ Jeremy Green
		 	  

		
	Name:	 	 Jeremy Green

		
	Title:	 	 Managing Member of the Investment Manager

		
	Dated:	 	 8/12/2015

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Redmile Special Opportunities Fund, Ltd.
		
	By:	 	/s/ Jeremy Green
		 	  

		
	Name:	 	 Jeremy Green

		
	Title:	 	 Managing Member of the Investment Manager

		
	Dated:	 	 8/12/2015

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Redmile Capital Offshore Fund II, Ltd.
		
	By:	 	/s/ Jeremy Green
		 	  

		
	Name:	 	 Jeremy Green

		
	Title:	 	 Managing Member of the Investment Manager

		
	Dated:	 	 8/12/2015

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Redmile Biotechnologies Investments I AF, LP
		
	By:	 	/s/ Jeremy Green
		 	  

		
	Name:	 	 Jeremy Green

		
	Title:	 	 Managing Member of the Mngt. Co./Investment Manager

		
	Dated:	 	 8/12/2015

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Cormorant Global Healthcare Master Fund, LP
		
	By:	 	/s/ Bihua Chen
		 	  

		
	Name:	 	 Bihua Chen

		
	Title:	 	 Managing Member of the General Partner

		
	Dated:	 	 August 12, 2015

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Clough Investment Partners I, L.P.
		
	By:	 	 /s/ Daniel J. Gillis

		 	  

		
	Name:	 	 Daniel J. Gillis

		
	Title:	 	 Chief Compliance Officer

		
	Dated:	 	 8/12/15

	
	  

	E-mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Clough Investment Partners II, L.P.
		
	By:	 	/s/ Daniel J. Gillis
		 	  

		
	Name:	 	 Daniel J. Gillis

		
	Title:	 	 Chief Compliance Officer

		
	Dated:	 	 8/12/15

	
	      

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Leerink Holdings LLC
		
	By:	 	 /s/ Timothy A.G. Gerhold

		 	  

		
	Name:	 	 Timothy A.G. Gerhold

		
	Title:	 	 General Counsel

		
	Dated:	 	 8/12/2015

	
	      

	E-Mail Address
	Copy to:	 	



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Leerink Swann Co-Investment Fund, LLC
		
	By:	 	 /s/ Jeffrey A. Leerink

		 	  

		
	Name:	 	 Jeffrey A. Leerink

		
	Title:	 	 Manager

		
	Dated:	 	 8/12/2015

	
	      

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Jennison Global Healthcare Master Fund, Ltd.
	
	By: Jennison Associates LLC, as the Investment Manager of Jennison Global Healthcare Master Fund, Ltd.
		
	By:	 	 /s/ David Chan

		 	  

		
	Name:	 	 David Chan

		
	Title:	 	 Managing Director of Jennison Associates LLC

		
	Dated:	 	 August 12, 2015

	
	      

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	SNBL USA, Ltd.
		
	By:	 	/s/ Ryoichi Nagata
		 	  

		
	Name:	 	 Ryoichi Nagata

		
	Title:	 	 Chairman

		
	Dated:	 	  

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Shin Nippon Biomedical Laboratories, Ltd.
		
	By:	 	/s/ Ryoichi Nagata
		 	  

		
	Name:	 	 Ryoichi Nagata

		
	Title:	 	 Chairman and CEO

		
	Dated:	 	  

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Kagoshima Shinsangyo Sousei Investment Limited Partnership
		
	By:	 	/s/ Masaharu Tanaka
		 	  

		
	Name:	 	 Masaharu Tanaka

		
	Title:	 	  

		
	Dated:	 	  

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Gregory L. Verdine
	Printed Name of Individual
	
	/s/ Gregory L. Verdine
	Signature of Individual
		
	Dated:	 	  

	
	  

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Takeshi Wada
	Printed Name of Individual
	
	/s/ Takeshi Wada
	Signature of Individual
		
	Dated:	 	 Aug. 13, 2015

	
	 
	E-mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 INVESTORS:

	
	Paul B. Bolno, M.D.
	Printed Name of Individual
	
	/s/ Paul B. Bolno, M.D.
	Signature of Individual
		
	Dated:	 	  

	
	      

	E-Mail Address



  
 SIGNATURE PAGE TO
INVESTORS’ RIGHTS AGREEMENT 








 SCHEDULE A 

Investors 
 Foresite Capital Fund III,
L.P. 
 101 California Street, Suite 4100 
 San Francisco,
CA 94111 
 Attention: Dennis D. Ryan 
 Email: 

Fidelity Select Portfolios: Biotechnology Portfolio 
 c/o
Brown Brothers Harriman & Co. 
 525 Washington Blvd 

Jersey City NJ 07310 
 Attn: Michael Lerman 15th Floor 

Corporate Actions 
 Email: 

Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund 

c/o State Street Bank & Trust 
 PO Box 5756 

Boston, MA 02206 
 Attn: Bangle & Co fbo Fidelity Advisor
Series VII: Fidelity Advisor Biotechnology Fund 
 Email: 

RA Capital Healthcare Fund, L.P. 
 20 Park Plaza, Suite
1200 
 Boston, MA 02116 
 (617) 778-2500 

Blackwell Partners LLC 
 20 Park Plaza, Suite 1200 

Boston, MA 02116 
 New Leaf Growth Fund I, L.P. 

7 Times Square, Suite 3502 
 New York, NY 10036 

Attn: Craig L. Slutzkin 
 Email: 

Redmile Fund, LP 
 c/o Redmile Group, LLC 

One Letterman Drive, Bld. D, Suite D3-300 
 San Francisco, CA
94129 







 Redmile Capital Offshore Fund, Ltd. 

c/o Redmile Group, LLC 
 One Letterman Drive, Bld. D, Suite D3-300

 San Francisco, CA 94129 
 Redmile Special Opportunities
Fund, Ltd. 
 c/o Redmile Group, LLC 
 One Letterman Drive,
Bld. D, Suite D3-300 
 San Francisco, CA 94129 
 Redmile
Capital Offshore Fund II, Ltd. 
 c/o Redmile Group, LLC 

One Letterman Drive, Bld. D, Suite D3-300 
 San Francisco, CA
94129 
 Redmile Biotechnologies Investments I AF, LP 

c/o Redmile Group, LLC 
 One Letterman Drive, Bld. D, Suite D3-300

 San Francisco, CA 94129 
 Cormorant Global Healthcare
Master Fund, LP 
 200 Clarendon Street, 52nd Floor 

Boston, MA 02116 
 Clough Investment Partners
II, L.P. 
 One Post Office Square, 40th Floor 

Boston, MA 02109 
 Leerink Holdings LLC 

One Federal Street, 37th Floor 
 Boston, MA 02110 

Leerink Swann Co-Investment Fund, LLC 
 One Federal
Street, 37th Floor 
 Boston, MA 02110 
 Jennison Global
Healthcare Master Fund, Ltd. 
 c/o Jennison Associates LLC 

466 Lexington Avenue 
 New York, New York 10017 

 

	
	Email:
	








 SNBL USA, Ltd. 

6605 Merrill Creek Parkway 
 Everett, WA 98203 

Shin Nippon Biomedical Laboratories Ltd. 
 6605 Merrill
Creek Parkway 
 Everett, WA 98203 
 Kagoshima Shinsangyo
Sousei Investment Limited Partnership 
 6-1-20 Nanei 

Kagoshim City, Kagoshima 
 821-0122 Japan 

099-260-3311 
 Gregory L. Verdine 

500 Atlantic Avenue, 18P 
 Boston, MA 02210 

Takeshi Wada 
 4-11-42-301 Asahi Cho 

Kashiwa, Chiba 277-0852, Japan 
 Email: 

Paul B. Bolno 
 113 W. Chestnut Hill Avenue 

Philadelphia, PA 19118 
 Email: